Table 1 Overview of the gliadin-reactive hmAbs.

hmAb	Selecting antigen	PLQPEQPFP reactivity⁵	DA 33mer reactivity⁵	CT gliadin reactivity⁵	Binding DA peptides >> NA peptide***⁵	# MS identified hmAb enriched peptides	Longest common 7mer motif in hmAb enriched peptides (% peptides pre/post hmAb pull-down)	# DA peptides pre/post hmAb pull-down
1002-1E01	PLQPEQPFP	Yes	Yes	Yes	No	139	QPQQPFP (39%/94%)	48%/77%
1130-3B04	Deamidated 33-mer	Yes	Yes	Yes	No	257	QPQQPFP (22%/95%)	88%/ 98%
1130-3A02	Deamidated 33-mer	Yes	Yes	Yes	No	21	QPQQPFP (37%/100%)	33%/43%
1130-2A02	Heat/acid treated CT gliadin	Yes	Yes	Yes	No	222	QPQQPFP (21%/92%)	26%/85%
1002-1E03	PLQPEQPFP	Yes	No	Yes	Yes	381	QPQQPFP (35%/95%)	27%/85%
1114-1G01	PLQPEQPFP	Yes	Yes	Yes	Yes	22	X₁QPQQPX₂ (X₁ = P, S; X₂ = I, L, F) (3%/100%)	33%/96%
1130-3B01	Deamidated 33-mer	Yes	Yes	Yes	2–3 log	48	QPQQXFP (X = P, S, T, Q) (49%/98%)	48%/82%
1130-3A05	Deamidated 33-mer	Yes	Yes	Yes	Not tested	552	QPQQPFP (25%/88%)	74%/100%
1130-3B03	Deamidated 33-mer	No	Yes	Yes	Yes	19	No common motif (<30%)	41%/9%
1130-3G05	Deamidated 33-mer	No	Yes	Yes	Yes	117 *	No common motif (<30%)	30%/29%
1050-5B05	Heat/acid treated CT gliadin	Yes	No	Yes	Not tested	23	X₁QPQQPX₂ (X₁ = Q P, I/L; X₂ = F, Q, A) (30%/83%)	27%/35%
1065-4C01	Heat/acid treated CT gliadin	No	No	Yes	Not tested	4	-	-
1065-4G05**	Heat/acid treated CT gliadin	No	No	Yes	Yes	0	-	-

Patient number, isolation method (selecting antigen denotes the antigen used to isolate the IgA⁺ plasma cells of which the hmAb was cloned) and reactivity to antigens in ELISA and/or AlphaLISA are shown as well as the number of hmAb-enriched peptides identified by MS, the most frequent 7mer motif among these peptides and % deamidated (DA) peptides pre/post hmAb pull-down.
^*31 peptides removed from the list as they were identified in the negative control sample.
^**For this hmAb 28 μg and not 40 μg was used in pull-down experiment.
^***Tested PLQPEQPFP/PLQPQQPFP for all hmAbs except for 3B03 and 3G05 where the DA and native α-gliadin 33mer was tested.

Search